Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium

Giorgia Zucchini, Filippo Montemurro

Research output: Contribution to journalArticle

Abstract

The San Antonio Breast Cancer Symposium is considered one of the most influential international meetings focusing on breast cancer management, covering several areas of study from basic research to clinical practice topics. a number of oral presentations addressing hormone receptor-positive breast cancer brought new data about critical subjects like the optimal duration of adjuvant endocrine therapy, new prognostic markers and their potential role in guiding adjuvant treatment choices, new insights into genomic alterations acquired during the metastatic process, and pharmacologic strategies to overcome resistance to endocrine therapy. This article aims at summarizing some of the presentations that, in our opinion, are expected to have an impact on clinical practice and research programs in this patient population.

Original languageEnglish
Pages (from-to)853-855
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number9
DOIs
Publication statusPublished - Jun 13 2017

Fingerprint

Hormones
Breast Neoplasms
Research
Therapeutics
Population
Pharmacological Phenomena

Keywords

  • aromatase inhibitors
  • buparlisib
  • endocrine therapy
  • everolimus
  • fulvestrant
  • gene-expression analysis
  • genomic alterations
  • Hormone-receptor
  • tamoxifen

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hormone-receptor positive breast cancer : highlights from the 39TH San Antonio Breast Cancer Symposium. / Zucchini, Giorgia; Montemurro, Filippo.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 9, 13.06.2017, p. 853-855.

Research output: Contribution to journalArticle

@article{25ab72978cbc402689a03cd0d5c4e039,
title = "Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium",
abstract = "The San Antonio Breast Cancer Symposium is considered one of the most influential international meetings focusing on breast cancer management, covering several areas of study from basic research to clinical practice topics. a number of oral presentations addressing hormone receptor-positive breast cancer brought new data about critical subjects like the optimal duration of adjuvant endocrine therapy, new prognostic markers and their potential role in guiding adjuvant treatment choices, new insights into genomic alterations acquired during the metastatic process, and pharmacologic strategies to overcome resistance to endocrine therapy. This article aims at summarizing some of the presentations that, in our opinion, are expected to have an impact on clinical practice and research programs in this patient population.",
keywords = "aromatase inhibitors, buparlisib, endocrine therapy, everolimus, fulvestrant, gene-expression analysis, genomic alterations, Hormone-receptor, tamoxifen",
author = "Giorgia Zucchini and Filippo Montemurro",
year = "2017",
month = "6",
day = "13",
doi = "10.1080/14656566.2017.1328500",
language = "English",
volume = "18",
pages = "853--855",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "9",

}

TY - JOUR

T1 - Hormone-receptor positive breast cancer

T2 - highlights from the 39TH San Antonio Breast Cancer Symposium

AU - Zucchini, Giorgia

AU - Montemurro, Filippo

PY - 2017/6/13

Y1 - 2017/6/13

N2 - The San Antonio Breast Cancer Symposium is considered one of the most influential international meetings focusing on breast cancer management, covering several areas of study from basic research to clinical practice topics. a number of oral presentations addressing hormone receptor-positive breast cancer brought new data about critical subjects like the optimal duration of adjuvant endocrine therapy, new prognostic markers and their potential role in guiding adjuvant treatment choices, new insights into genomic alterations acquired during the metastatic process, and pharmacologic strategies to overcome resistance to endocrine therapy. This article aims at summarizing some of the presentations that, in our opinion, are expected to have an impact on clinical practice and research programs in this patient population.

AB - The San Antonio Breast Cancer Symposium is considered one of the most influential international meetings focusing on breast cancer management, covering several areas of study from basic research to clinical practice topics. a number of oral presentations addressing hormone receptor-positive breast cancer brought new data about critical subjects like the optimal duration of adjuvant endocrine therapy, new prognostic markers and their potential role in guiding adjuvant treatment choices, new insights into genomic alterations acquired during the metastatic process, and pharmacologic strategies to overcome resistance to endocrine therapy. This article aims at summarizing some of the presentations that, in our opinion, are expected to have an impact on clinical practice and research programs in this patient population.

KW - aromatase inhibitors

KW - buparlisib

KW - endocrine therapy

KW - everolimus

KW - fulvestrant

KW - gene-expression analysis

KW - genomic alterations

KW - Hormone-receptor

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85019541943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019541943&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1328500

DO - 10.1080/14656566.2017.1328500

M3 - Article

C2 - 28481697

AN - SCOPUS:85019541943

VL - 18

SP - 853

EP - 855

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -